Walvax Biotechnology Co., Ltd. Class A

Walvax Biotechnology Co., Ltd. Class A

SSZSE:300142
10.38
CNY
-0.13
(-1.24%)
0.01EPS
1,042.28P/E
22.76BMarket Cap
Mar 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.41
0.5
0.72
0.42
0.43
0.57
0.73
1.91
2.21
3.17
2.57
1.76
1.51
1.15
Basic EPS, GAAP
0.03
0.1
-0.6
0.05
-0.35
0.68
0.09
0.65
0.27
0.45
0.26
0.09
0.11
0.01
Free Cash Flow per Basic Share
-0.36
-0.21
-0.24
-0.24
-0.22
-0.19
-0.19
-0.19
-0.25
0.07
0.12
0.3
-0.01
- -
Dividend per Share
0.07
0.12
0.11
0.09
0.02
- -
0.04
0.02
0.05
0.03
0.01
0.03
0.02
0.17
Book Value per Share
1.95
2.05
1.63
2.09
1.97
2.98
3.16
4.23
5.3
5.65
5.82
5.9
5.39
4.34
Tangible Book Value per Share
0.49
0.81
0.46
1.2
0.96
2.42
2.49
3.47
4.37
4.74
4.87
4.95
4.51
3.43
Basic Weighted Avg Shares
1,437
1,434
1,401
1,409
1,537
1,537
1,538
1,539
1,569
1,603
1,600
1,599
1,600
1,599
Sales/Revenue/Turnover
583
719
1,006
591
668
879
1,121
2,939
3,463
5,086
4,114
2,821
2,418
1,846
Operating Margin (%)
13.29
-26.45
-15.65
-16.38
3.16
11.95
14.64
34.75
25.02
26.18
24.86
10.34
14.1
11.22
Depreciation Expense
126
117
73
102
109
116
77
124
144
265
317
389
392
- -
Net Income, GAAP
48
143
-841
70
-537
1,046
142
1,003
428
729
419
142
178
22
Effective Tax Rate (%)
52.61
29.9
- -
13.45
- -
10.21
15.39
11.8
15.18
12.35
14.63
5.48
24.66
65.63
Profit Margin (%)
8.21
19.95
-83.59
11.92
-80.38
119.02
12.66
34.13
12.35
14.33
10.19
5.04
7.35
1.18
Working Capital
812
805
179
1,051
771
2,602
2,355
3,351
4,445
5,440
5,529
4,697
2,609
1,983
LT Debt
988
991
595
100
256
181
- -
2
1
342
455
445
206
844
Total Equity
2,938
3,212
3,024
3,524
3,557
5,262
5,666
7,848
9,999
10,990
11,395
11,508
9,536
7,285
Return on Invested Capital (%)
0.04
1.75
- -
-3.03
- -
23.48
3.53
17.9
6.61
8.87
4.44
0.76
1.32
- -
Return on Capital (%)
2.82
6
- -
4.94
- -
22.18
2.06
11.73
2.84
4.83
2.81
0.97
2.09
- -
Return on Common Equity (%)
1.68
5.1
-32.55
2.57
-17.23
27.51
3.01
17.58
5.69
8.3
4.55
1.51
1.97
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
433
413
561
LT Borrowings
917
836
836
LT Finance Leases
13
8
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,599
1,599
1,599
Market Capitalization
19,816
20,776
22,759

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
4,329
4,046
3,939
Cash, Cash Equivalents & STI
970
767
907
Accounts Receivable, Net
2,288
2,008
1,718
Inventories
562
602
618
Total Current Liabilities
2,002
1,950
1,957
Payables & Accruals
- -
- -
- -
ST Debt
433
413
561
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.65%
4.97%
-17.13%
Free Cash Flow
2.15%
6.7%
-103.83%
Net Income, GAAP
-81.58%
-14.1%
25.03%
Sales/Revenue/Turnover
19.29%
-0.02%
-14.29%
Total Cash Common Dividend
134.8%
27.66%
-29.18%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
600
834
708
680
2,821
2025
462
692
- -
699
2,418
2026
444
390
313
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.1
0.05
-0.07
0.09
2025
- -
0.03
- -
0.01
0.11
2026
0.07
-0.04
-0.03
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
- -
0.01
0.03
2025
- -
0.01
- -
- -
0.02
2026
0.03
0.13
0.01
- -
- -

Company Description

CEO
Yao Wei
Full Time Employees
1,981
Sector
Health technology
Industry
Biotechnology
Address
No. 395 Kexin Road Kunming YU China 650101
IPO Date
Oct 29, 2010
Website
walvax.com
Business
Walvax Biotechnology Co., Ltd. Walvax Biotechnology Co., Ltd. (300142.SZ) is a China-based biopharmaceutical company principally engaged in the research, development, production and distribution of human vaccines. The company offers a portfolio of vaccines including 13-valent pneumococcal polysaccharide conjugate vaccine for infants and children; 23-valent pneumococcal polysaccharide vaccine; group A and C meningococcal polysaccharide conjugate vaccine; group A and C meningococcal polysaccharide vaccine; ACYW135 group meningococcal polysaccharide vaccine; haemophilus influenzae type b conjugate vaccine for children; diphtheria, tetanus and acellular pertussis combined vaccine (DTaP) for infants and children; recombinant bivalent human papillomavirus vaccine (types 16/18, HPV-2, or Pichy yeast); SARS-CoV-2 mRNA vaccines such as ARCoV and Omicron XBB.1.5 variant; and recombinant subunit COVID-19 vaccines. Founded in 2001 and headquartered in Kunming, Yunnan Province, China, Walvax operates primarily in the domestic market with exports to countries including Indonesia, Morocco, Egypt, and the Philippines, and maintains advanced R&D platforms for polysaccharide, conjugate, recombinant protein, VLP and mRNA vaccines. In recent developments, Walvax's recombinant bivalent HPV vaccine (HPV-2) received World Health Organization prequalification in August 2024 and launched commercially in China in 2022; its SARS-CoV-2 mRNA vaccine (Omicron XBB.1.5) obtained Emergency Use Authorization from China's NMPA; and its 13-valent pneumococcal conjugate vaccine was exported to Morocco for inclusion in the national immunization program. The company expanded collaborations with CEPI and Shanghai Zerun Biotechnology for COVID-19 multi-variant vaccines, including Phase I/II trials in Mali supported by up to USD 8.15 million in funding. In July 2025, Walvax signed a three-year global strategy cooperation framework agreement with Yuxi State-owned Capital Operation Co., Ltd. to support industrial upgrades, equity optimization and mergers in innovative vaccines and biologics; and in November 2025, entered a two-year memorandum of understanding with Mirxes Holding Company Limited for an RNA-centric preventive medicine platform encompassing joint development, trials and commercialization leveraging mRNA technologies and ASEAN distribution. Walvax continues partnerships with global organizations such as WHO, UNICEF, PATH, GAVI, CEPI, DCVMN and the Bill & Melinda Gates Foundation to advance affordable vaccines for emerging diseases.